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Abstract The respiratory tract is constantly exposed to the
external environment, and therefore, must be equipped to re-
spond to and eliminate pathogens. Viral clearance and resolu-
tion of infection requires a complex, multi-faceted response
initiated by resident respiratory tract cells and innate immune
cells and ultimately resolved by adaptive immune cells.
Although an effective immune response to eliminate viral
pathogens is essential, a prolonged or exaggerated response
can damage the respiratory tract. Immune-mediated pulmo-
nary damage is manifested clinically in a variety of ways
depending on location and extent of injury. Thus, the antiviral
immune response represents a balancing act between the elim-
ination of virus and immune-mediated pulmonary injury. In
this review, we highlight major components of the host re-
sponse to acute viral infection and their role in contributing
to mitigating respiratory damage. We also briefly describe
common clinical manifestations of respiratory viral infection
and morphological correlates. The continuing threat posed by
pandemic influenza as well as the emergence of novel respi-
ratory viruses also capable of producing severe acute lung
injury such as SARS-CoV, MERS-CoV, and enterovirus
D68, highlights the need for an understanding of the immune
mechanisms that contribute to virus elimination and immune-
mediated injury.
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Introduction
The cells that line the respiratory tract are continually exposed
to the external environment, making the lungs a particularly
vulnerable site for infection. Respiratory infections represent a
major disease and economic burden worldwide. According to
the CDC, influenza virus infection and associated complica-
tions are one of the top ten causes of death and result in
millions of hospitalizations, costing over $10 billion each year
in the USA [1]. Other respiratory virus such as highly patho-
genic avian influenza and Severe Acute Respiratory
Syndrome (SARS-CoV) and Middle Eastern Respiratory
Syndrome (MERS-CoV) coronaviruses represents ever-
present threats to human health globally. Therefore, under-
standing the factors, both virus-dependent and host-depen-
dent, that regulate the development and severity of respiratory
virus infections is critical for both the prevention and treat-
ment of virus-associated disease in the respiratory tract.
A limited survey of respiratory viral infections reveals that
respiratory viruses with distinct virion and genome structures,
unique entry receptors, and modes of replication, cause similar
clinical syndromes and sequelae (Table 1). These clinical ob-
servations and a growing body of experimental data suggest
that the host response to infection rather than direct viral injury
of respiratory cells primarily accounts for the clinical and path-
ologic changes observed during respiratory viral infections.
This review, therefore, provides a brief overview of the contri-
bution of host responses to lung pathology during primary
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acute virus infections rather than pathology caused directly by
virus. A detailed, comprehensive comparison of the differences
among respiratory viruses is not discussed here.
Direct viral injury
A virus must replicate and orchestrate the assembly of virion
constituents to produce progeny virus and propagate itself.
This often happens at the expense of the infected cell. A radical
but ultimately effective response to stop virus replication is for
the infected cell to self-destruct via apoptosis although some
viruses have evolved strategies to circumvent this [2].
Cytopathology or death by starvation can also result from virus
usurpation of host cellular machinery and metabolic processes
[2]. Thus, death of infected cells caused directly by virus does
play some role in lung pathology during infection. However,
much of the clinical sequelae and damage to respiratory cells is
a result of the host response to virus and virus-infected cells.
Response of the host
Viral sensing
Nearly all body cells have mechanisms to detect viruses (and
other microbial pathogens) by pattern recognition receptors
(PRRs) which recognize pathogen-associated molecular pat-
terns (PAMPs) or molecules associated with viral andmicrobial
pathogens but not typically found in host cells. PRRs that are
important for detection of viruses include Toll-like receptors
(TLRs), retinoic acid-inducible gene I (RIG-I), NOD-like re-
ceptors (NLRs), and other cytosolic virus sensors. Although
these receptors are expressed in many types of cells, their acti-
vation in respiratory epithelial cells, typically among the first
cell types to be infected, is critical in limiting virus spread and
alerting the immune system to respond to the infection.
Activation of PRRs in these cells by virus infection triggers
production and release of type I and III interferons (IFNs) and
other proinflammatory mediators (e.g., cytokines, chemokines,
and antimicrobial peptides) which initiate the host innate and
adaptive immune response. Thus, the degree of PRR activation
throughout the respiratory tract ultimately influences the degree
of immune cell recruitment and proinflammatory mediator re-
lease and subsequently, any immunopathology ensued.
Interferon response
Type I IFNs (IFN-α and IFN-β)
Many different types of cellular sensors can detect viruses and
induce the expression of the type I IFNs—IFN-α and IFN-β.
Type I IFNs bind to the ubiquitously expressed IFNAR
(IFN-α/β receptor), activating the JAK/STAT pathway [3].
Table 1 Clinical presentation of respiratory viral infections
Virus Entry receptor Common symptoms Clinical complications
Rhinovirus ICAM-1 or LDL Rhinorrhea, coryza, sneezing, sore
throat, cough
Asymptomatic, mild to moderate upper-respiratory
tract illness, bronchitis
Common coronavirus Strain specific Fever, rhinorrhea, coryza, sneezing,
sore throat, cough
Mild to moderate upper-respiratory tract illness
Adenovirus Strain specific penton Fever, rhinorrhea, coryza, sneezing,
sore throat, cough, pink eye,
diarrhea, bladder infections
Mild to moderate upper-respiratory tract illness,
croup, tonsilitis
Seasonal influenza Sialic acids Fever, rhinorrhea or stuffy nose, coryza,
sore throat, cough, headache, myalgia
Mild to moderate upper-respiratory tract illness,
bronchitis, croup
RSV Nucleolin Fever, rhinorrhea, coryza, sore throat,
cough, wheezing, shortness of breath
Mild to moderate upper-respiratory tract illness,
bronchitis, bronchiolitis, croup
Enterovirus D68 Sialic acids alpha2-6 Rhinorrhea, sneezing, cough, mouth
blisters, myalgia; wheezing and
dyspnea in more severe cases
Mild to moderate upper-respiratory tract illness,
bronchitis, bronchiolitis, pneumonia
Pandemic influenza Sialic acids Fever, coryza, rhinorrhea or stuffy
nose, sore throat, cough, headache,
shortness of breath, dyspnea, myalgia
Bronchitis, croup, pneumonia, diffuse alveolar
damage, acute respiratory distress syndrome,
respiratory failure
SARS-CoV ACE2 Fever, chills, cough, shortness of breath,
dyspnea, myalgia
Rapidly progressive pneumonia, diffuse alveolar
damage, severe acute respiratory distress
syndrome, respiratory failure, fibrosis
MERS-CoV CD26 Fever, chills or rigors, coryza, sore
throat, non-productive cough, sputum
production, shortness of breath,
dyspnea, headache, vomiting, diarrhea,
myalgia
Rapidly progressive pneumonia, diffuse alveolar
damage, severe acute respiratory distress
syndrome, respiratory failure, septic shock and
multi-organ failure
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The type I IFN response can induce the expression of hun-
dreds of interferon stimulated genes (ISGs) which primarily
serve to limit further virus spread and infection. However,
type I IFNs can also directly activate immune cells (e.g., stim-
ulating phagocytosis, dendritic cell maturation) as well as in-
directly initiate immune responses (e.g., stimulating the pro-
duction of chemokines and cytokines by respiratory cells).
Intrinsic antiviral activity by type I IFNs includes impairing
viral processes such as cell entry, replication, transcription,
and translation [4]. Other ISG products can degrade viral
nucleic acids or proteins, and many ISGs have yet to be fully
characterized.
In addition to their intrinsic antiviral activity, type I IFNs
promote the initiation of the adaptive immune response by
mediating dendritic cell (DC) activation, enhancing effector
functions of lymphocytes and macrophages, and stimulating
the humoral (antibody) response to neutralize virus. Type I
IFNs have a significant impact on DCs by (1) stimulating
the differentiation and maturation of monocytes into DCs,
(2) promoting migration of DCs to lymph nodes through in-
duction of chemokine receptors, (3) enhancing antigen (Ag)
presentation to CD4 T cells and cross-presentation to CD8 T
cells, and (4) upregulating costimulatory molecules requisite
for naïve T cell activation and effector T cell generation [3].
Thus, type I IFNs play an indirect role in orchestrating adap-
tive immune responses through the activation of DCs.
Type I IFNs directly enhance the functional activities of
lymphocytes. They stimulate the production and secretion of
IFN-γ (type II IFN) which in turn activates macrophages and
phagocytosis, enhances Ag presentation by DCs, and directly
limits viral replication [5]. Type I IFNs also augment cytotoxic
activity of T cells and natural killer (NK) cells, thereby facil-
itating clearance of virus-infected cells and preventing further
dissemination of the virus [5]. IFNs promote the humoral im-
mune response indirectly through DC and T cell activation,
but they can also directly activate B cells and promote a robust
and effective virus-specific antibody response [6].
Type III IFNs (IL-28A/IFN-λ1, IL-28B/IFN-λ2,
and IL-29/IFN-λ3)
Unlike IFNAR which is expressed in nearly all body cells,
expression of the receptor for type III IFNs—IFNLR or inter-
feron lambda receptor—and IFN-λ production is limited in the
lungs primarily to epithelial cells [3]. Like type I IFNs, type III
IFNs activate the JAK/STATsignaling pathway and thus, elic-
it similar intrinsic and extrinsic antiviral biological activities
as described above for type I IFNs in airway epithelium [7, 8].
Interestingly, in response to viral stimuli, human airway epi-
thelial cells produce greater amounts of IFN-λ than type I
IFNs and thus, type III IFNs may be more effective against
viral infection in respiratory cells than type I IFNs [8, 9].
As a consequence of their widespread effects on host im-
mune responses, IFNs indirectly facilitate much of the inflam-
mation and injury in the lungs during acute virus infection.
Epithelial cells
Cytokines, chemokines, and other factors discussed in this
section are also secreted by many types of immune cells
(discussed later), and therefore will cause similar pathological
or protective effects.
Cytokines
Airway epithelial cells secrete a host of cytokines,
chemokines, antimicrobial peptides and other factors in re-
sponse to viral infection. Cytokines beyond the IFNs pro-
duced by airway epithelium include interleukin-6 (IL-6), tu-
mor necrosis factor-α (TNF-α), granulocyte colony stimulat-
ing factor (G-CSF), and granulocyte macrophage-CSF (GM-
CSF). IL-6 and TNF-α are potent proinflammatory cytokines
that modulate many types of immune cells. IL-6 facilitates the
transition from the innate to adaptive immune response by
driving down neutrophil activity while concurrently promot-
ing the recruitment, differentiation, and activity of monocytes
and T cells [10]. High IL-6 levels correlate with disease sever-
ity, but ablation of IL-6 signaling can lead to uncontrolled
virus replication resulting in greater mortality [11]. TNF-α
impairs viral replication, enhances cytotoxic activity, and cy-
tokine production by leukocytes and activates endothelial
cells [12]. Elevated levels of TNF-α have been associated
with greater morbidity during infection with highly pathogen-
ic virus, and blocking activity of TNF-α attenuates immune-
mediated pathology [11].
G-CSF and GM-CSF both induce differentiation of myeloid
lineage cells. G-CSF stimulates the production, differentiation,
proliferation, and survival of neutrophils thereby mobilizing
one of the first responders—neutrophils [13]. GM-CSF stimu-
lates the proliferation and differentiation of various types of
immune progenitor cells. In the lungs, GM-CSF induces the
expansion and activation of pulmonary DCs and macro-
phages—immune responses necessary for an effective T cell
response and viral clearance [14, 15]. Mice deficient in GM-
CSF signaling are highly susceptible to respiratory viral infec-
tion, and exogenous delivery of GM-CSF is protective [15, 16].
Chemokines
Chemokines produced by respiratory epithelium stimulate the
migration of both innate and adaptive immune cells to the
lungs. IL-8/CXCL8 recruits neutrophils to the lungs, stimu-
lates degranulation, and the subsequent release of cytotoxic
and inflammatory mediators and may support neutrophil sur-
vival [17]. Elevated levels of IL-8 have been implicated in the
Semin Immunopathol (2016) 38:471–482 473
pathogenesis of acute respiratory distress syndrome (ARDS)
due to tissue damage likely caused by excessive release of
neutrophil proteases and reactive oxygen species (ROS) [17].
IP-10/CXCL10 stimulates the chemotaxis of T cells, NK
cells, and monocytes in addition to promoting monocyte and
DC activation in concert with other cytokines. CXCL10/IP-10
may be protective in some cases since neutralization of IP-10
worsens disease caused by respiratory viral infection [18]. In
other cases, CXCL10/IP-10 may contribute to extensive leu-
kocyte recruitment, propagating a heightened inflammatory
response and immune-mediated lung injury [19, 20].
CCL5/RANTES recruits several types of leukocytes: T
cells, NK cells, monocytes, DCs, and granulocytes. In addi-
tion to its chemotactic properties, CCL5 can also activate T
cells, monocytes, NK cells, and DCs promoting a diverse
range of immune responses important in controlling virus in-
fection and generating protective immunity [21]. In response
to RSV (respiratory syncytial virus) infection, CCL5 may ex-
acerbate inflammation and airway hyperreactivity [22], but
deletion of CCL5 in response to influenza virus infection leads
to decreased survival in mice [23]. Thus, the levels of CCL5
and type of viral pathogen may determine whether this che-
mokine is beneficial or detrimental to the host during infec-
tion. Respiratory epithelium also produces several other
chemokines whose role in protecting or contributing to pul-
monary pathology is not entirely clear. While most
chemokines released by respiratory cells in response to
PRRs, IFNs, and proinflammatory cytokines are not inherent-
ly pathogenic in of themselves, redundant or concerted che-
motaxis and/or substantial amounts of chemokines may in-
duce excessive leukocyte infiltration and activity, damaging
respiratory epithelium.
Antimicrobial products and other secreted factors
Respiratory epithelial cells secrete numerous broad-spectrum
antimicrobial/antiviral products that directly inhibit respirato-
ry pathogens and in some cases, modulate immune responses.
The most abundant antimicrobial factors in the lungs are ly-
sozyme, lactoferrin, and secretory leukocyte proteinase inhib-
itor (SLPI) [24]. Lactoferrin, a glycoprotein secreted by mu-
cosal epithelium, can prevent both DNA and RNA viruses
from infecting cells by directly binding virus and blocking
host receptors used by viruses to gain entry into cells [25].
Lysozyme and SLPI while effective against some microbial
pathogens have limited antiviral capabilities in the lungs.
However, SLPI plays a major role in protecting mucosal epi-
thelium from damaging proteolytic enzymes released by epi-
thelia and inflammatory cells, thus, limiting lung injury and
promoting wound healing [26].
Airway epithelial cells produce substantial amounts of β-
defensins—cationic peptides that exert both antimicrobial and
antiviral properties [24]. β-defensins neutralize viruses,
induce cytokine production by epithelial cells, and recruit im-
mature DCs and memory T cells [24]. Cathelicidins (LL37)
also exert broad-spectrum antimicrobial properties and can
disrupt the envelopes of viruses, recruit immune cells, and
enhance chemokine and cytokine production from local cells,
promoting inflammatory responses [27].
Respiratory epithelial cells constitutively produce nitric ox-
ide (NO) which is further increased by exposure to proinflam-
matory cytokines and respiratory viruses [28]. NO and prod-
ucts formed by NO activity inhibit viral proteins, transcription
and replication [29]. The indiscriminate activity of NO can
also modify host cellular proteins and induce generation of
toxic cellular species such as free radicals and reactive nitro-
gen intermediates that damage pulmonary epithelium [29, 30].
Alveolar type II epithelial cells constitutively produce and
secrete four surfactant proteins (SP-A, −B, −C, and −D). SP-B
and SP-C contribute to the properties of surfactant which re-
duces the surface tension in the alveoli; thus, SP-B and SP-C
serve a critical role in pulmonary function but have limited
antiviral activity [30]. Hydrophilic SP-A and SP-D function as
collectins—secreted, soluble PRRs that recognize many viral
and microbial PAMPs and enhance opsonization of patho-
gens. Targeting viruses by these collectins facilitates phago-
cytosis and clearance by macrophages and neutrophils [31].
Endothelial cells
Although respiratory epithelial cells are the primary targets of
most respiratory viruses, infection of endothelium by virus
can occur but is highly dependent on the viral pathogen and
frequently is species-specific. For example, human RSV pro-
ductively infects pulmonary vascular endothelium leading to
endothelial cell activation but also cell death [32]. In contrast,
influenza viruses generally do not infect human endothelium
although some effectively replicate within avian endothelium
[33]. Therefore, the degree to which endothelial cells contrib-
ute to respiratory pathogenesis depends in part on virus tro-
pism and the direct cytopathic effects and cytokine signaling
induced by a replicating virus (similar to virus-infected respi-
ratory epithelium). Viruses that infect endothelium may in-
duce more significant lung injury particularly to the alveolar
epithelium as a result of increased vascular permeability, ede-
ma, and spatial proximity to alveolar cells. Hantavirus, unlike
most respiratory viruses, primarily targets microvascular en-
dothelium causing significant microvascular leakage and pul-
monary edema [34]; notably, hantavirus pulmonary syn-
drome—characterized by the filling of the lungs with flu-
id—has a mortality rate of 38 %.
Release of proinflammatory cytokines, NO, and ROS from
epithelium and leukocytes can enhance endothelial permeabil-
ity and disrupt the integrity of the endothelial-epithelial barrier
[35]. Damage to alveolar epithelium can expose and increase
the susceptibility of localized endothelium to injury. Increased
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vascular permeability and pulmonary edema impairs efficient
gas exchange between the airways and blood, resulting in
respiratory distress. Thus, endothelium damage caused direct-
ly by virus or indirectly by inflammatory processes can play a
significant role in pulmonary injury in response to respiratory
infection.
Regardless of infectivity of endothelium, endothelial cells
play an essential role in leukocyte migration and can modulate
the immune response, particularly early innate immune re-
sponses to virus infection. Extravasation of immune cells into
the lungs from the circulation (or alternatively resident pulmo-
nary DC migration to the draining lymph nodes) is highly
dependent on interactions between endothelium and leuko-
cytes. Selectins and adhesion molecules requisite for extrava-
sation are upregulated on endothelium in response to cyto-
kines and growth factors secreted by respiratory epithelium
and other neighboring cells [35]. Activated endothelium can
also secrete proinflammatory cytokines and chemokines such
as IL-6, MIG/CXCL9, IP-10/CXCL10, type I and type II
IFNs, MCP-1/CCL2, and TNF-α in response to a virus infec-
tion [35]. Inhibition of these processes in endothelial cells in
an animal model of lethal influenza infection greatly improved
survival [36]. Thus, endothelial cells can facilitate pulmonary
injury by heightened leukocyte recruitment and cytokine se-
cretion during a highly pathogenic virus infection. The extent
of pulmonary tissue that is infected or damaged and the
amounts of proinflammatory cytokines and chemokines gen-
erated in response, influences the degree of endothelial acti-
vation. Ultimately, if uncontrolled or too extensive, these pro-
cesses can be more damaging than beneficial by recruiting
more immune cells that either injure the lungs directly or fur-
ther propagate inflammation causing a Bcytokine storm.^
However, insufficient leukocyte recruitment or cytokine pro-
duction can leave the host susceptible to the virus.
Alveolar macrophages
Alveolar macrophages—the tissue-resident macrophages of
the lungs—are localized to the airspaces within alveoli,
uniquely positioning them to respond to threats to the lower
airways. During homeostasis, alveolar macrophages regularly
encounter innocuous antigens. To prevent inappropriate in-
flammatory responses to these benign antigens, the lung envi-
ronment maintains alveolar macrophages in a suppressive
state. Negative regulation of alveolar macrophages is accom-
plished through expression of IL-10, alphaV/beta6 integrin,
GM-CSF, CD200 receptor, and pulmonary surfactants by al-
veolar epithelium [37]. Upon respiratory virus infection, the
environment of the alveolar sac quickly changes, and expres-
sion of the negative regulators declines. This change in the
lung environment coupled with detection of viral antigens and
exposure to proinflammatory mediators enables alveolar mac-
rophages to adopt a proinflammatory phenotype, which assists
in initiating the host immune response and viral clearance.
While the mechanism of protection remains unclear, a grow-
ing body of evidence has demonstrated that alveolar macro-
phages are essential during respiratory viral infection. For ex-
ample, during RSV infection, they are responsible for early
cytokine and IFN production that orchestrates the initial anti-
viral response [38].
Neutrophils
Among the first immune cells to arrive to the site of infection,
neutrophils excel in eliminating infected cells and clearing
microbial pathogens, dead cells, and debris. Neutrophils are
generally not productively infected by respiratory viruses but
do phagocytose virions, viral particles, and apoptotic bodies
containing virus [39]. Once phagocytosed, neutrophils utilize
a host of proteolytic enzymes and antimicrobial peptides re-
leased from intracellular granules and ROS produced by
NAPDH oxidase to kill or inactivate pathogens [40].
Neutrophil granules and their contents may also be secreted
and released extracellularly. Some of the antimicrobial pep-
tides secreted by neutrophils include defensins, lactoferrin,
lysozyme, and cathelicidins (LL-37). In addition to these
mechanisms, neutrophils can form and release neutrophil ex-
tracellular traps (NETs)—molecular traps composed of
decondensed chromatin, histones, proteases, and antimicrobi-
al proteins [41]. The release of NETs immobilizes pathogens
and prevents further dissemination.
Sufficient neutrophil recruitment and activity control virus
dissemination and mitigate severe disease. However, an ex-
cessive neutrophil response can be detrimental to the host by
causing uncontrolled inflammation and indiscriminate dam-
age to respiratory epithelium [39]. ROS, hydrolytic enzymes
and myeloperoxidase released into the extracellular space can
injury alveolar epithelium and endothelium [35]. A genetic
deficiency in NAPDH oxidase—the enzyme responsible for
ROS production and implicated in NET formation—attenu-
ates lung injury and improves recovery from influenza virus
infection in mice [42]. NETs may also damage respiratory
epithelium and endothelium possibly by exposure to hydro-
lytic enzymes and cytotoxic proteins [35].
In addition to their phagocytic and cytotoxic activities, neu-
trophils can mediate both innate and adaptive immune pro-
cesses. Neutrophils secrete chemokines that can recruit more
neutrophils to the site of inflammation; elevated levels of these
chemokines have been associated with more severe lung pa-
thology during infection [17, 19, 20, 43]. Normally neutro-
phils undergo apoptosis, NETosis (programmed death that
results in the formation of NETs), or some other form of cel-
lular death and therefore, inflammatory and cytotoxic activity
of this non-specific, potent granulocyte is typically short-
lived. Apoptotic bodies and debris left by apoptotic neutro-
phils is then cleared by macrophages. However, if
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programmed cellular death of neutrophils or clearance by
macrophages is impaired, both respiratory and immune cells
may be exposed to damaging or activating factors propagating
severe inflammation and acute lung injury [44].
Although historically the role of neutrophils in the immune
response has been centered on inflammatory and innate re-
sponses, novel roles for neutrophils in shaping the adaptive
immune response have emerged. Some neutrophils can express
B cell-activating cytokines that support B cell activity and may
function as BB-cell helper^ neutrophils [40]. Neutrophils can
suppress Tcell responses through the production of suppressive
factors such as inducible nitric oxide synthase (iNOS) and ar-
ginase 1. In other cases, neutrophils may promote T cell re-
sponses through the secretion of IFN-γ or Ag presentation
[40, 45]. The mechanisms that neutrophils utilize to support
adaptive immune responses during respiratory viral infections
and the impact that these activities have on viral clearance,
injury and recovery will need to be investigated further.
Innate lymphocytes
NK cells
Natural killer (NK) cells are part of a family of innate lymphoid
cells (ILC) that includes ILC1, −2 and −3. The role of ILC
(other than NK cells) during respiratory virus infection is un-
clear although ILC2 have been reported to facilitate repair after
lung injury [46]. NK cells respond to viral infection within a
few days producing significant amounts of IFN-γ, killing
virus-infected cells, and supporting the adaptive immune re-
sponse. NK cells are uniquely equipped with a diverse set of
receptors that enable them to distinguish normal cells (via in-
hibitory receptors) from virus-infected or transformed cells (via
activating receptors). Activating receptors can recognize viral
or tumor antigens—allowing the NK cells to eliminate both
infected and tumor cells. In response to chemokines, additional
NK cells are recruited within a few days (following neutrophil
recruitment but prior to the arrival of effector T cells) and fa-
cilitate the transition from the initial, potent inflammatory re-
sponses to the more specific adaptive response [47].
Activation of NK cells triggers cytotoxic activity which
eliminates virus-infected cells. NK cells kill infected cells by
releasing cytotoxic granules, engaging death receptors, or uti-
lizing antibody-dependent cell-mediated cytotoxicity
(ADCC)—a process in which antibodies bind viral proteins
expressed on the surface of infected cells marking them for
elimination [47, 48]. All of these cytotoxic processes promote
viral clearance and limit viral spread. However, viruses such
as some strains of influenza virus have adapted mechanisms to
activate inhibitory receptor signaling, preventing NK-
mediated killing [47]. Additionally, despite inefficient viral
replication within NK cells, infection of NK cells by some
respiratory viruses can induce apoptosis limiting the numbers
of NK cells and thus, early cytotoxic functions to control viral
dissemination [39]. Depletion of pulmonary NK cells impairs
viral clearance and subsequently, leads to more severe disease
[47, 49]. NK cells also augment CTL (cytotoxic T lympho-
cyte) activity through IFN-γ production [49, 50]. In some
viral infections such as RSV, robust production of IFN-γ by
NK cells may contribute to lung injury [51]. Therefore, the
type of virus and inoculating dose may influence whether NK
cells contribute to lung pathology or not. Finally, NK cells
have recently been shown to secrete IL-22 which promotes
tissue repair mechanisms [52]. Overall, NK cells appear to
primarily have a beneficial role during respiratory viral infec-




Natural killer T cells (NKTs) represent a heterogeneous pop-
ulation of T cells that possess properties of both NK and T
cells. NKTs may be classified as either type I (or invariant
NKT cells) or type II NKT cells depending on the type of
TCR expressed [53]. The best-characterized and most studied
subset of NKTs in the context of viral infections is invariant
NKT (iNKT) cells which express a semivariant TCR that rec-
ognizes lipid molecules—most likely endogenous self lipids
during viral infection since viruses lack exogenous lipid anti-
gens. Cytokines may also activate iNKTs during respiratory
viral infection. iNKTs support effector responses but also limit
the degree of lung injury by regulating other immune re-
sponses and virus-mediated sequelae. iNKTs support CTL
and NK responses through cytokine production and promot-
ing the licensing, cross-priming and maturation of DCs, and
limiting the immunosuppressive activity of virally induced
myeloid-derived suppressor cells (MDSCs) [53, 54]. iNKTs
limit inflammation-mediated damage by regulating inflamma-
tory monocyte activity and promote repair processes during
the recovery phase through the secretion of IL-22 [54]. Mice
deficient in iNKTs suffer from more severe disease in re-
sponse to RSV or influenza virus infection [54]. iNKT cells
exhibit multi-faceted roles in modulating the immune re-
sponse to viral pathogens and appear to be mostly beneficial
in limiting lung injury during acute infection.
γδ T cells
In contrast to αβ T cells, γδ T cells express TCRs of limited
diversity composed of γδ chains instead of αβ chains and
predominantly reside within mucosal or non-lymphoid tissues
such as the skin, lungs, and intestine [55]. Because γδ T cells
are mostly tissue-resident cells, it has been suggested that they
may serve an important role in the initial response and defense
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against pathogens [55]. In the lungs, γδ T cells can suppress
inflammation and help regulate other immune responses to
mitigate severe lung injury and promote tissue repair [55,
56]. In patients that survived SARS-CoV infection, expansion
of an effector memory γδ T cell population capable of pro-
ducing IFN-γ and directly killing SARS-CoV-infected cells
may have protected them from succumbing to SARS [56]. In
other cases, γδ T cells promote inflammatory processes by
secreting proinflammatory cytokines and chemokines, con-
tributing to more severe disease [57]. In response to lung
injury, γδ T cells promote tissue repair and protect against
pulmonary fibrosis through the secretion of IL-22 and sup-
pression of other immune cells [55, 58]. Contradicting func-
tional roles for γδ Tcells during respiratory infection might be
attributed to different viruses, the functions of certain subsets
of γδ T cells, or different activity by γδ T cells during the
various phases of infection.
Dendritic cells
Dendritic cells (DCs) represent a diverse population of cells that
serve as fundamental orchestrators of the immune response.
DCs activate Tcells, secrete various cytokines and chemokines,
and promote protective adaptive immunity. Some DC subsets
preferentially reside in either lymphoid or non-lymphoid tissue;
while other subsets can migrate between these tissues. Under
normal, non-inflamed conditions, respiratory DC populations
can be found below and within conducting airway epithelium
as well as in the lower airways within the walls of alveoli [59].
Thus, they are strategically positioned to sample antigens
throughout the upper and lower respiratory tract. In mice, res-
ident pulmonary DCs include conventional CD11b+ DCs and
CD103+ DCs as well as plasmacytoid DCs (pDCs) [59].
Human pulmonary DC populations similarly include pDCs
and two subsets of myeloid DCs that functionally resemble
the CD11b+ (CD1+ DCs) and CD103+ (CD141+/CLEC 9A
DCs) subsets found in mice [39]. In response to infection, some
CD103+ and CD11b+ DCs acquire viral antigens and migrate
to the draining lymph nodes (DLN) activating adaptive im-
mune responses while other DCs remain in the lungs promoting
local immune responses [59, 60]. Nonresident monocyte-
derived DCs (mo-DCs) also accumulate in the lungs as inflam-
matory monocytes migrate into the lungs and differentiate into
either macrophages or DCs. DCs can be activated directly by
virus through PRRs and indirectly by proinflammatory
chemokines and cytokines released by respiratory epithelium
and other resident immune cells [59].
Conventional DCs
In the lungs, CD103+ DCs are mostly associated with the mu-
cosal epithelium of the conducting airways and function pri-
marily as APCs, activating both CD8 and CD4 T cell
proliferation and differentiation through antigen presentation
[59, 61]. CD103+ DCs migrate to the DLN within 2–4 days
following infection where they efficiently activate both CD4
and CD8 naïve and memory T cells that recognize viral anti-
gens [63, 64]. CD103+ DCs are the most robust stimulators of
naïve CD8 Tcell activation and elicit protective CD8 immunity
because they express receptors for uptake of apoptotic bodies
containing virus and efficiently cross-present exogenously ac-
quired antigens [59–61]. Both CD103+ and CD11b+ DCs ac-
tivate naïve CD4 Tcells, drive T helper 1 (Th1) responses, and
generate effective memory T cell populations to protect against
subsequent infections [61]. CD11b+ DCs are also capable of
presenting antigen and activating both CD4 and CD8 T cell
responses to control respiratory viral infection but differ in a
few distinct ways from the CD103+ DC population. CD11b+
DCs arrive a bit later to the draining lymph nodes (5–7 days
after infection) where they may promote expansion of previ-
ously activated effector CD8 Tcells and secrete robust amounts
of proinflammatory chemokines [59, 61].
pDCs
pDCs are potent producers of type I IFNs during respiratory
viral infection, and thus play a role in the initial sensing of
viral pathogens and initiating inflammatory and innate im-
mune responses. Unexpectedly, in response to influenza virus,
the absence of pDCs had no effect on viral clearance or dis-
ease severity [62]. Although pDCs can transport viral antigens
from the lungs to the DLN, pDCs are poor stimulators of naïve
T cell activation and differentiation due to low expression of
costimulatory molecules [59, 61]. Thus, pDCs may be dis-
pensable during certain respiratory viral infections. In re-
sponse to RSV infection, however, pDCs may suppress in-
flammation and promote viral clearance, protecting against
severe lung injury [62]. The precise functions of pDCs during
respiratory viral infections warrant further study to understand
how different subsets of pDCs in response to different viruses
contribute to viral clearance, modulation of the immune re-
sponse, and lung injury.
Monocyte-derived DCs
A large fraction of mo-DCs initially arrive in the lungs as
Bmonocytes^ which then differentiate into DCs in response
to type I IFNs and direct infection with virus [59, 60]. These
mo-DCs can support naïve CD8 T cell activation, Th1 differ-
entiation and cytotoxic effector functions [59]. They can also
further propagate an inflammatory response through the pro-
duction of CXCL10/IP-10 and CCL2/MCP-1, recruiting more
inflammatory monocytes to the lungs. During a recall re-
sponse, mo-DCs may activate cytotoxic responses of memory
CD8 T cells and NK cells through cytokine production, en-
abling swift and efficient pathogen clearance [60]. Elevated
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numbers of mo-DCs that express CCR2 (chemokine receptor
for CCL2) or produce high amounts of TNF-α and NO are
associated with greater morbidity and mortality in response to
viral infection [11, 59, 60]. While blocking mo-DC activity or
deficiency in CCR2 improves survival and mitigates severe
lung pathology in experimental virus infection, complete de-
pletion of mo-DCs leads to uncontrolled virus spread and
more severe disease [11, 59]. Thus, a balanced response by
DCs that promotes viral clearance and effector responses with-
out eliciting too much inflammation is probably the key in
controlling virus- or immune-mediated lung injury.
Inflammatory monocytes
Inflammatory monocytes are recruited from the circulation to
the lungs following viral infection. They produce type I IFNs
and chemokines and can differentiate into DCs (as discussed
above) or macrophages which promote viral clearance, cyto-
toxic activity, and T cell activation [63]. Potentially, a defect in
inflammatory monocyte activity or recruitment could impact
any of these immune processes. Since inflammatorymonocytes
depend on CCR2 to migrate to the lungs, a deficiency in this
chemokine receptor impairs the recruitment of inflammatory
monocytes (and the subsequent populations derived from
them) which results in improved survival and diminished lung
pathology [11, 59]. However, a defect in the CD8+ T cell re-
sponse and viral clearance may also occur when the CCR2+
population is completely eliminated. An attenuated rather than
complete deletion of the inflammatory monocyte response has
been shown to allow effective viral clearance while limiting
inflammatory and immune-mediated damage to the lungs [11,
63]. Similarly to mo-DCs, the role of inflammatory monocytes
in lung pathology may be detrimental or beneficial depending
on the degree of the response and viral pathogen.
Adaptive immune responses
Although the innate immune response plays a significant role
in initiating both antiviral responses and adaptive immune re-
sponses, ultimately the adaptive immune response is responsi-
ble for complete viral clearance by halting viral replication to
prevent the generation of new virions and eliminating infec-
tious virions. Because adaptive immune cells are dependent
on early innate immune responses, this does not, however,
mitigate the role of innate immune response to virus infection.
Humoral immune response: B cells and CD4 helper T cells
B cells contribute to virus clearance predominantly through
production of virus-specific antibodies which can (1) neutral-
ize, opsonize, and inactivate virions or (2) initiate killing of
infected cells. Preventing the spread of infectious virions from
infected cells to neighboring cells is essential to controlling
virus dissemination. Neutralizing antibodies produced by B
cells effectively prevent free virions from invading uninfected
cells by blocking surface proteins on the virus that bind to host
receptors for cellular entry. Viruses coated in antibodies are
also tagged for inactivation by complement proteins or elim-
ination by phagocytic immune cells such as macrophages and
neutrophils. Antibodies can bind to viral proteins expressed on
the surface of infected cells, triggering the complement cas-
cade and antibody-mediated cell-mediated cytotoxicity
(ADCC)—processes that ultimately eliminate infected cells.
Although essential to viral clearance, these cytotoxic process-
es if extensive can compromise respiratory function through
the loss of airway epithelium, disruption of the epithelial-
endothelial barrier, and accumulation of apoptotic bodies
and cellular debris in the airways.
A subset of subset of CD4 T cells called follicular helper T
(TFH) cells play a critical role in facilitating an effective B cell
response during infection. Adoptively transferred CD4 T cells
protect athymic mice (mice that lack functional T cells) from
succumbing to influenza infection. However, when CD4 T
cells are adoptively transferred into SCID (severe combined
immunodeficiency) mice that lack functional T and B cells,
CD4 T cells are no longer sufficient for protection, and deple-
tion of CD4 T cells during SARS-CoV infection coincided
with a reduction in antibody production [64]. During infec-
tion, TFH cells promote the formation of germinal centers in
secondary lymphoid tissues where virus-specific B cells ma-
ture, proliferate, undergo antibody class switching, and differ-
entiate into either antibody-producing plasma cells or long-
term memory cells. TFH cell numbers have been shown to
correlate with the production of influenza-specific IgG and
IgM antibodies after vaccination in healthy young adults [65].
Antibody-mediated protection is the goal of many vaccine
strategies because of its critical role in viral clearance. Each
year influenza vaccines are administered in order to enrich cir-
culating neutralizing antibodies specific to that year’s predicted
strains. This strategy has been substantiated by data demon-
strating that rhinovirus and influenza-neutralizing antibodies
in the serum, prior to infection, correlate with disease protection
[66]. Similarly, a neutralizing antibody response to the spike
glycoprotein of SARS-CoV has also been shown to be
completely protective for a susceptible host although antibody
titers are relatively short lived [67]. One of the disadvantages to
a vaccine that primarily elicits an antibody response, though, is
the lack of a protective, cell-mediated immune response which
is particularly important in the context of viral infections.
Cell-mediated immune response: CD8+ T cells
Clearance of intracellular pathogens, such as viruses, requires
elimination of the infected cells. Athymic mice which produce
mature T cells (but do have an intact antibody response), do not
recover from influenza infection due to the inability to clear
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virus. SARS-CoV are relatively new pulmonary viruses whose
pathogeneses are still being elucidated; however, research indi-
cates that CD8 Tcells are essential for virus clearance. Adoptive
transfer of SARS-CoV-activated T cells into SCID mice en-
hanced survival and reduced pulmonary virus titers [68]. Thus,
the elimination of virus-infected cells through cell-mediated im-
munity is important to completely resolve infection. The primary
function of CD8 T cells during respiratory viral infections is the
elimination of virus-infected cells by inducing apoptosis through
a variety of mechanisms. CD8 T cells engage death receptors
such as FAS expressed by virus-infected cells and release
perforin and granzymes which create pores in the cell membrane
and initiate apoptotic pathways, respectively.
While essential, adaptive immune-mediated clearance of
virus-infected cells can compromise the respiratory tract, and
if unregulated, will cause catastrophic injury to the host tissue.
This has been demonstrated in multiple models of adaptive
immune deficient mice. Despite not being able to clear virus,
RAG1 (recombination-activation gene-1) knockout mice that
lack both functional T and B cells have delayed morbidity and
mortality after high dose inoculation with influenza virus [69].
Furthermore, virus-specific CD8 T cells in RAG1 knockout
mice exacerbate lung injury and accelerate mortality [69].
During experimental RSV infection, depletion of both CD4
and CD8 T cells enabled continued virus replication, but no
illness was evident [70]. Ultimately, the adaptive immune re-
sponse is required for resolution of infection and confers long-
term protection from future encounters with the virus,
preventing future disease; however, the adaptive immune re-
sponse is also very potent and if extensive, can cause sufficient
respiratory damage to impair pulmonary function.
Immunopathology
Normal respiratory function is dependent on the preservation
of pulmonary architecture and the endothelial-epithelial barri-
er between the airways and circulation. During viral infection,
pulmonary architecture is frequently compromised primarily
by the host immune response and to a lesser extent directly by
virus replication in most cases. The extent of structural alter-
ation, functional compromise and subsequently, clinical man-
ifestations of infection are dependent on many factors but
most prominently on the degree of virus dissemination
throughout the respiratory tract.
Infection of the upper respiratory tract (URT)
Often the URT is the initial site of viral replication since many
respiratory viruses are inhaled or transferred by contact to the
nasal mucosa. In healthy patients without pre-existing condi-
tions, infections with common strains of rhinovirus, coronavi-
rus, and adenovirus are typically limited to the upper airways.
Symptomatic viral infection of the URT (coryza, rhinorrhea,
cough, and sore throat) (Table 1) reflects loss of cellular tight
junctions, vascular leakage and edema, increased mucus pro-
duction, and apoptosis, necrosis, and sloughing of epithelial
cells [71–73]. Recruitment of neutrophils and mononuclear
cells into the URT further propagates edema and hyper-
secretion of mucus, exacerbating nasal congestion, sneezing,
and coughing in patients [71–73].
Bronchitis and bronchiolitis
Viruses capable of producing more severe infections such as
influenza, proceed from the URT to the LRT where they dis-
seminate to the bronchi and bronchioles and if not controlled,
alveoli. Patient monitoring during respiratory viral infection
corroborates this, as upper respiratory illness precedes any
LRT (lower respiratory tract) symptoms. Among respiratory
viruses, influenza viruses, SARS-CoV, and MERS-CoV are
commonly capable of spreading into the bronchi and bronchi-
oles in otherwise healthy individuals. However, in infants and
young children, RSV frequently infects small conducting air-
ways and is a leading cause of pediatric hospitalization world-
wide [74]. Enterovirus d68 is also capable of rapid progression
to the conducting airways and gained particular notoriety in
2014 after an outbreak in the USA resulted in significant pedi-
atric hospitalization with severe respiratory compromise and
increased mortality.
Infection of the bronchi and bronchioles leads to similar
cellular changes and localized inflammation as in URT infec-
tions. However, because of the progressively decreasing di-
ameter of LRT conducting airways, inflammation and injury
in this compartment—e.g., desquamation of airway epithelial
cells in response to RSVor airway epithelial cell hyperplasia
during influenza infection—results in more severe compro-
mise of respiratory function. The absence of ciliated epithelial
cells in the LRT limits the expulsion of mucus, proteinaceous
fluid, bacteria, and cellular fragments from these airways. This
is compounded by enhanced epithelial mucus secretion, vas-
culature leak, edema, mucosal inflammation, and epithelial
sloughing. The influx of inflammatory cells in response to
signals from infected epithelium and tissue resident innate
immune cells increases edema, vascular congestion, and tissue
swelling further limiting air passage through smaller airways.
The buildup of edematous fluid, mucus and fibrin plugs in
small bronchi and bronchioles can restrict airflow to terminal
airways further preventing efficient gas exchange. Increased
pressure within the blood vessels leaks more fluid into the
airspaces. As all these factors build up in the already restricted
bronchi and bronchioles, they begin to clot and form plugs
that prevent gas exchange. This manifests clinically as wheez-
ing and shortness of breath. In serious cases, this can lead to
difficulty in breathing which requires oxygen therapy.
Typically with supportive care, bronchitis and bronchiolitis
will resolve in a few days without lasting effects.
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Pneumonia
While viruses such as RSV and Enterovirus D68 are capable
of reaching the terminal airways, influenza viruses and the
SARS-CoV and MERS-CoV coronaviruses more frequently
reach the terminal airways, and thus are more likely to disrupt
pulmonary function and cause pneumonia [72]. The terminal
airways are the site of gas exchange and make up the majority
of the airway surface of the lung. During infection, loss of
tight junctions, vasculature leak, buildup of edematous fluid
and fibrin in the alveolar airspaces can result in necrosis of the
alveolar cells and hyaline membrane formation. If severe,
these changes can lead to diffuse alveolar damage (DAD),
manifested clinically as ARDS and respiratory failure.
Inflammatory processes and immune responses as described
previously compromise the function and properties of termi-
nal airways and terminal airway epithelial cells in a fashion
analogous to that of conducting airways. Furthermore, a loss
of surface tension and surfactant resulting in alveolar collapse
represent additional threats to pulmonary function in the ter-
minal airways. The terminal airways of survivors of acute
viral pneumonia can result in alteration of pulmonary elastic-
ity due to organization of inflammatory processes during the
resolution phase which may have lasting consequences and
put the host at risk for superinfections [72, 73, 75]. Although
not discussed here, bacterial superinfection or co-infection are
important sequelae of virus infection in the LRT particularly
during influenza virus infection.
Conclusions
Not surprisingly, the immunopathology of respiratory virus
infection reflects a complex interplay involving direct effects
by a given virus and other viral factors but also the response of
resident respiratory cells and recruited innate and adaptive
immune cells to the lungs. Studies carried out over the last
several decades suggest that in most—but not all—instances,
the host response to respiratory virus infection (rather than the
direct effects of virus replication) dictates the type and extent
of injury incurred.
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